{"pmid":32453877,"title":"Delayed-Phase Thrombocytopenia in Patients of Coronavirus Disease 2019 (COVID-19).","text":["Delayed-Phase Thrombocytopenia in Patients of Coronavirus Disease 2019 (COVID-19).","COVID-19 can affect the hematopoietic system. Thrombocytopenia at admission was prevalent, while late-phase or delayed-phase thrombocytopenia (occurred 14 days after symptom onset) is obscure. This retrospective single-center study screened 450 COVID-19 patients and enrolled 271 patients at the Union Hospital, Wuhan, China, from January 25th to March 9th, 2020. COVID-19 associated delayed-phase thrombocytopenia occurred in 11.8% percent of enrolling patients. The delayed-phase thrombocytopenia in COVID-19 is prone to develop in elderly patients or patients with low lymphocyte count on admission. The delayed-phase thrombocytopenia is significantly associated with increased length of hospital stay and higher mortality rate. Delayed-phase nadir platelet counts demonstrated a significantly negative correlation with B cell percentages. We also presented bone marrow aspiration pathology of three patients with delayed-phase thrombocytopenia, showing impaired maturation of megakaryocytes. We speculated that immune mediated platelet destruction might account for the delayed-phase thrombocytopenia in a group of patients. Besides, clinicians need to pay attention to the delayed-phase thrombocytopenia especially at 3-4 weeks after symptom onset.","Br J Haematol","Chen, Wanxin","Li, Ziping","Yang, Bohan","Wang, Ping","Zhou, Qiong","Zhang, Zhiguo","Zhu, Jianhua","Chen, Xuexing","Yang, Peng","Zhou, Hao","32453877"],"abstract":["COVID-19 can affect the hematopoietic system. Thrombocytopenia at admission was prevalent, while late-phase or delayed-phase thrombocytopenia (occurred 14 days after symptom onset) is obscure. This retrospective single-center study screened 450 COVID-19 patients and enrolled 271 patients at the Union Hospital, Wuhan, China, from January 25th to March 9th, 2020. COVID-19 associated delayed-phase thrombocytopenia occurred in 11.8% percent of enrolling patients. The delayed-phase thrombocytopenia in COVID-19 is prone to develop in elderly patients or patients with low lymphocyte count on admission. The delayed-phase thrombocytopenia is significantly associated with increased length of hospital stay and higher mortality rate. Delayed-phase nadir platelet counts demonstrated a significantly negative correlation with B cell percentages. We also presented bone marrow aspiration pathology of three patients with delayed-phase thrombocytopenia, showing impaired maturation of megakaryocytes. We speculated that immune mediated platelet destruction might account for the delayed-phase thrombocytopenia in a group of patients. Besides, clinicians need to pay attention to the delayed-phase thrombocytopenia especially at 3-4 weeks after symptom onset."],"journal":"Br J Haematol","authors":["Chen, Wanxin","Li, Ziping","Yang, Bohan","Wang, Ping","Zhou, Qiong","Zhang, Zhiguo","Zhu, Jianhua","Chen, Xuexing","Yang, Peng","Zhou, Hao"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32453877","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/bjh.16885","keywords":["covid-19","sars-cov-2","clinical features","cytokine","lymphocyte","thrombocytopenia"],"locations":["Thrombocytopenia","thrombocytopenia","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667881798485409792,"score":9.490897,"similar":[{"pmid":32302435,"title":"Thrombocytopenia and its association with mortality in patients with COVID-19.","text":["Thrombocytopenia and its association with mortality in patients with COVID-19.","BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes novel coronavirus disease 2019 (COVID-19), is spreading rapidly around the world. Thrombocytopenia in patients with COVID-19 has not been fully studied. OBJECTIVE: To describe thrombocytopenia in patients with COVID-19. METHODS: For each of 1476 consecutive patients with COVID-19 from Jinyintan Hospital, Wuhan, China, nadir platelet count during hospitalization was retrospectively collected and categorized into (0, 50], (50, 100], (100-150], or (150-) groups after taking the unit (x10(9) /L) away from the report of nadir platelet count. Nadir platelet counts and in-hospital mortality were analyzed. RESULTS: Among all patients, 238 (16.1%) patients were deceased and 306 (20.7%) had thrombocytopenia. Compared with survivors, non-survivors were older, were more likely to have thrombocytopenia, and had lower nadir platelet counts. The in-hospital mortality was 92.1%, 61.2%, 17.5%, and 4.7% for (0, 50], (50, 100], (100-150], and (150-) groups, respectively. With (150-) as the reference, nadir platelet counts of (100-150], (50, 100], and (0, 50] groups had a relative risk of 3.42 (95% confidence interval [CI] 2.36-4.96), 9.99 (95% CI 7.16-13.94), and 13.68 (95% CI 9.89-18.92), respectively. CONCLUSIONS: Thrombocytopenia is common in patients with COVID-19, and it is associated with increased risk of in-hospital mortality. The lower the platelet count, the higher the mortality becomes.","J Thromb Haemost","Yang, Xiaobo","Yang, Qingyu","Wang, Yaxin","Wu, Yongran","Xu, Jiqian","Yu, Yuan","Shang, You","32302435"],"abstract":["BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes novel coronavirus disease 2019 (COVID-19), is spreading rapidly around the world. Thrombocytopenia in patients with COVID-19 has not been fully studied. OBJECTIVE: To describe thrombocytopenia in patients with COVID-19. METHODS: For each of 1476 consecutive patients with COVID-19 from Jinyintan Hospital, Wuhan, China, nadir platelet count during hospitalization was retrospectively collected and categorized into (0, 50], (50, 100], (100-150], or (150-) groups after taking the unit (x10(9) /L) away from the report of nadir platelet count. Nadir platelet counts and in-hospital mortality were analyzed. RESULTS: Among all patients, 238 (16.1%) patients were deceased and 306 (20.7%) had thrombocytopenia. Compared with survivors, non-survivors were older, were more likely to have thrombocytopenia, and had lower nadir platelet counts. The in-hospital mortality was 92.1%, 61.2%, 17.5%, and 4.7% for (0, 50], (50, 100], (100-150], and (150-) groups, respectively. With (150-) as the reference, nadir platelet counts of (100-150], (50, 100], and (0, 50] groups had a relative risk of 3.42 (95% confidence interval [CI] 2.36-4.96), 9.99 (95% CI 7.16-13.94), and 13.68 (95% CI 9.89-18.92), respectively. CONCLUSIONS: Thrombocytopenia is common in patients with COVID-19, and it is associated with increased risk of in-hospital mortality. The lower the platelet count, the higher the mortality becomes."],"journal":"J Thromb Haemost","authors":["Yang, Xiaobo","Yang, Qingyu","Wang, Yaxin","Wu, Yongran","Xu, Jiqian","Yu, Yuan","Shang, You"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302435","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14848","keywords":["covid-19","sars-cov-2","generalized linear model","mortality","thrombocytopenia"],"locations":["Thrombocytopenia","Jinyintan Hospital","Wuhan","China","thrombocytopenia","thrombocytopenia","Thrombocytopenia","Thrombocytopenia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138494801543172,"score":426.09174},{"pmid":32483524,"pmcid":"PMC7255984","title":"Isolated severe thrombocytopenia in a patient with COVID-19: A case report.","text":["Isolated severe thrombocytopenia in a patient with COVID-19: A case report.","COVID-19 is known to cause serious respiratory symptoms and involvement of other body systems such as hematopoietic, neurological and the immune system. In this report, we described a case of a COVID-19 patient who presented with no pulmonary involvement but severe thrombocytopenia. She suffered from headache and malaise with no respiratory symptoms, fever or chills. Chest radiological imaging was unremarkable but, the laboratory results showed significant thrombocytopenia associated with relatively decreased lymphocytes. Based on her high-risk work environment, a reverse transcription polymerase chain reaction (RT-PCR) test was performed and SARS-CoV-2 RNA was detected in the nasopharyngeal swab. Complete blood count (CBC) of patient was re-checked during admission and platelet count showed rising trend up to normal levels. A narrow diagnostic approach where only febrile patients with pulmonary symptoms are evaluated for a COVID-19 diagnosis will result in many missed diagnoses; so it is important that physicians are familiar with atypical and rare presentations of COVID-19, such as isolated thrombocytopenia.","IDCases","Sadr, Sara","SeyedAlinaghi, SeyedAhmad","Ghiasvand, Fereshteh","Hassan Nezhad, Malihe","Javadian, Nina","Hossienzade, Roghieh","Jafari, Fatemeh","32483524"],"abstract":["COVID-19 is known to cause serious respiratory symptoms and involvement of other body systems such as hematopoietic, neurological and the immune system. In this report, we described a case of a COVID-19 patient who presented with no pulmonary involvement but severe thrombocytopenia. She suffered from headache and malaise with no respiratory symptoms, fever or chills. Chest radiological imaging was unremarkable but, the laboratory results showed significant thrombocytopenia associated with relatively decreased lymphocytes. Based on her high-risk work environment, a reverse transcription polymerase chain reaction (RT-PCR) test was performed and SARS-CoV-2 RNA was detected in the nasopharyngeal swab. Complete blood count (CBC) of patient was re-checked during admission and platelet count showed rising trend up to normal levels. A narrow diagnostic approach where only febrile patients with pulmonary symptoms are evaluated for a COVID-19 diagnosis will result in many missed diagnoses; so it is important that physicians are familiar with atypical and rare presentations of COVID-19, such as isolated thrombocytopenia."],"journal":"IDCases","authors":["Sadr, Sara","SeyedAlinaghi, SeyedAhmad","Ghiasvand, Fereshteh","Hassan Nezhad, Malihe","Javadian, Nina","Hossienzade, Roghieh","Jafari, Fatemeh"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32483524","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.idcr.2020.e00820","keywords":["coronavirus disease 2019 (covid-19)","lymphopenia","severe acute respiratory syndrome coronavirus 2 (sars-cov-2)","thrombocytopenia"],"topics":["Case Report"],"weight":1,"_version_":1668704334431387648,"score":358.57898},{"pmid":32178975,"pmcid":"PMC7102663","title":"Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis.","text":["Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis.","BACKGROUND: Coronavirus disease 2019 (COVID-19) is a novel infectious disease with lack of established laboratory markers available to evaluate illness severity. In this study, we investigate whether platelet count could differentiate between COVID-19 patients with or without severe disease. Additionally, we evaluate if thrombocytopenia is associated with severe COVID-19. METHODS: An electronic search in Medline, Scopus and Web of Science was performed to identify studies reporting data on platelet count in COVID-19 patients. A meta-analysis was performed, with calculation of weighted mean difference (WMD) of platelet number in COVID-19 patients with or without severe disease and odds ratio (OR) of thrombocytopenia for severe form of COVID-19. RESULTS: Nine studies with 1779 COVID-19 patients, 399 (22.4%) with severe disease, were included in the meta-analysis. The pooled analysis revealed that platelet count was significantly lower in patients with more severe COVID-19 (WMD -31 x 10(9)/L; 95% CI, from -35 to -29 x 10(9)/L). A subgroup analysis comparing patients by survival, found an even lower platelet count was observed with mortality (WMD, -48 x 10(9)/L; 95% CI, -57 to -39 x 10(9)/L. In the four studies (n = 1427) which reported data on rate of thrombocytopenia, a low platelet count was associated with over fivefold enhanced risk of severe COVID-19 (OR, 5.1; 95% CI, 1.8-14.6). CONCLUSIONS: Low platelet count is associated with increased risk of severe disease and mortality in patients with COVID-19, and thus should serve as clinical indicator of worsening illness during hospitalization.","Clin Chim Acta","Lippi, Giuseppe","Plebani, Mario","Henry, Brandon Michael","32178975"],"abstract":["BACKGROUND: Coronavirus disease 2019 (COVID-19) is a novel infectious disease with lack of established laboratory markers available to evaluate illness severity. In this study, we investigate whether platelet count could differentiate between COVID-19 patients with or without severe disease. Additionally, we evaluate if thrombocytopenia is associated with severe COVID-19. METHODS: An electronic search in Medline, Scopus and Web of Science was performed to identify studies reporting data on platelet count in COVID-19 patients. A meta-analysis was performed, with calculation of weighted mean difference (WMD) of platelet number in COVID-19 patients with or without severe disease and odds ratio (OR) of thrombocytopenia for severe form of COVID-19. RESULTS: Nine studies with 1779 COVID-19 patients, 399 (22.4%) with severe disease, were included in the meta-analysis. The pooled analysis revealed that platelet count was significantly lower in patients with more severe COVID-19 (WMD -31 x 10(9)/L; 95% CI, from -35 to -29 x 10(9)/L). A subgroup analysis comparing patients by survival, found an even lower platelet count was observed with mortality (WMD, -48 x 10(9)/L; 95% CI, -57 to -39 x 10(9)/L. In the four studies (n = 1427) which reported data on rate of thrombocytopenia, a low platelet count was associated with over fivefold enhanced risk of severe COVID-19 (OR, 5.1; 95% CI, 1.8-14.6). CONCLUSIONS: Low platelet count is associated with increased risk of severe disease and mortality in patients with COVID-19, and thus should serve as clinical indicator of worsening illness during hospitalization."],"journal":"Clin Chim Acta","authors":["Lippi, Giuseppe","Plebani, Mario","Henry, Brandon Michael"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32178975","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.cca.2020.03.022","keywords":["coronavirus, covid-19","platelets","thrombocytopenia"],"locations":["thrombocytopenia","Medline","Scopus","thrombocytopenia","Thrombocytopenia"],"topics":["Mechanism"],"weight":1,"_version_":1666138490589413377,"score":334.59265},{"pmid":32420612,"title":"COVID-19-associated immune thrombocytopenia.","text":["COVID-19-associated immune thrombocytopenia.","Thrombocytopenia is a risk factor for increased morbidity and mortality in patients with the new severe acute respiratory syndrome corona virus, SARS-CoV-2 infection (COVID-19 infection).(1) Thrombocytopenia in COVID-19 patients may be caused by disseminated intravascular coagulation (DIC), sepsis or drug-induced. Recently a single case report suggested immune thrombocytopenia (ITP) may be associated with COVID-19 infection.(2) ITP is a rare autoimmune disease characterized by a platelet count < 100x10(9) /L, leading to an increased bleeding risk.(3) Several risk factors have been described for ITP including environmental (e.g. infection, malignancy and drugs) and genetic predisposition.(4) We report here the first case series of three patients with ITP associated with COVID-19 infection.","Br J Haematol","Bomhof, G","Mutsaers, P G N J","Leebeek, F W G","Te Boekhorst, P A W","Hofland, J","Croles, F N","Jansen, A J G","32420612"],"abstract":["Thrombocytopenia is a risk factor for increased morbidity and mortality in patients with the new severe acute respiratory syndrome corona virus, SARS-CoV-2 infection (COVID-19 infection).(1) Thrombocytopenia in COVID-19 patients may be caused by disseminated intravascular coagulation (DIC), sepsis or drug-induced. Recently a single case report suggested immune thrombocytopenia (ITP) may be associated with COVID-19 infection.(2) ITP is a rare autoimmune disease characterized by a platelet count < 100x10(9) /L, leading to an increased bleeding risk.(3) Several risk factors have been described for ITP including environmental (e.g. infection, malignancy and drugs) and genetic predisposition.(4) We report here the first case series of three patients with ITP associated with COVID-19 infection."],"journal":"Br J Haematol","authors":["Bomhof, G","Mutsaers, P G N J","Leebeek, F W G","Te Boekhorst, P A W","Hofland, J","Croles, F N","Jansen, A J G"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420612","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bjh.16850","locations":["Thrombocytopenia","Thrombocytopenia"],"topics":["Case Report"],"weight":1,"_version_":1667254896710123520,"score":294.47543},{"pmid":32296910,"title":"Mechanism of thrombocytopenia in COVID-19 patients.","text":["Mechanism of thrombocytopenia in COVID-19 patients.","Since December 2019, a novel coronavirus has spread throughout China and across the world, causing a continuous increase in confirmed cases within a short period of time. Some studies reported cases of thrombocytopenia, but hardly any studies mentioned how the virus causes thrombocytopenia. We propose several mechanisms by which coronavirus disease 2019 causes thrombocytopenia to better understand this disease and provide more clinical treatment options.","Ann Hematol","Xu, Panyang","Zhou, Qi","Xu, Jiancheng","32296910"],"abstract":["Since December 2019, a novel coronavirus has spread throughout China and across the world, causing a continuous increase in confirmed cases within a short period of time. Some studies reported cases of thrombocytopenia, but hardly any studies mentioned how the virus causes thrombocytopenia. We propose several mechanisms by which coronavirus disease 2019 causes thrombocytopenia to better understand this disease and provide more clinical treatment options."],"journal":"Ann Hematol","authors":["Xu, Panyang","Zhou, Qi","Xu, Jiancheng"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296910","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s00277-020-04019-0","keywords":["coronavirus disease 2019","platelet","severe acute respiratory syndrome coronavirus 2","thrombocytopenia"],"locations":["China","thrombocytopenia","thrombocytopenia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493207707648,"score":292.8652}]}